**MINUTES**

**CPIC CONFERENCE CALL**

DATE: March 5, 2015

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link after each conference call. |
| HLA-B/allopurinol guideline update | This guideline was a minor update (changes to supplemental material only). Kelly (on behalf of the guideline authors) presented the updated tables, evidence table and implementation tables/figures to CPIC members. The literature review yielded 26 relevant primary studies showing association between *HLA-B\*58:01* and allopurinol SCAR. In addition, 12 studies showed associations for *HLA-A\*33:03* (7 studies) or *HLA-C\*03:02* (5 studies. However, the strength of the evidence did not warrant inclusion in this update. Kelly sent this guideline to CPIC members on March 3rd for CPIC review. | Please send any comments/edits to Kelly by March 12th. |
| CPIC guidelines in progress | - *CYP2D6*/SSRI: In review- *CYP3A5*/tacrolimus: Accepted-*UGT1A1*/atazanavir: Evidence review complete; writing underway-CYP2D6/tamoxifen: This effort will be led by Teri Klein and Matt Goetz. The authorship plan has been approved by the CPIC Steering Committee. Evidence review underway.-*CYP2C19*/voriconazole: Working on authorship plan; will start guideline development in next few weeks. Guideline Updates:- *HLA-B*/allopurinol: See above- CYP2C9/VCORC1, warfarin: Evidence review underway. | Kelly will follow-up. |
| CPIC Term Standardization Project-Delphi 1 results | Kelly presented results from the first survey to CPIC members (https://www.pharmgkb.org/page/cpicTermProject). 59 experts with varying degrees of pharmacogenetic expertise (clinicians, researchers, genetic clinical laboratories, etc.) responded to the survey. On the first survey (Delphi 1), experts were asked to specify their level of agreement or disagreement on a symmetric agree-disagree scale (i.e. strongly disagree, disagree, agree, strongly agree) for each gene. For the next survey (Delphi 2), terms in which 70% of the experts agreed or strongly agreed and related terms will be retained. We will also group together related terms (e.g. sets that encompass all phenotypes/allele function for that gene—increased function, normal function, decreased function, no function). Experts will be asked to specify their level of acceptance to the set of terms listed for each gene(s) and explain if they feel the terms are unacceptable. Members provided ideas on the next round of surveys including providing scenarios/examples which might help guide responses and asking experts if acceptable to have the same terms for all CYP enzymes.  | Kelly will continue to update CPIC members on the progress of this project. |